The World Health Organization (WHO) estimates that counterfeit drugs in the supply chain cost manufacturers $40 billion annually, and prompt safety recalls minimize product liability and potential compliance fines.
It is expected that full implementation of the DSCSA will improve patient safety by creating a system that makes it easier to identify counterfeit drugs, and quicker to remove them out of the supply chain. The same system will also speed up the process for pulling back a legitimate drug from the supply chain in the event of a safety recall.
In this white paper, we reveal:
Download the white paper now and find out.
“I’ll be honest—it’s night and day inventory control...We went from an item-level only inventory to having true visibility of item, location and lot number with RFgen.”
Senior Business Analyst | Life Extension
“With RFgen, I have observed several benefits, including better traceability and productivity. RFgen is simple to use, so there is less adaptation time for our employees.”
Yip Chi Ming
Regional Operations Manager | DSM